Evidence map›Paper›PMID 39470061›Full record

ArticleJournal of the American Heart Association2024

Epigenetic Study of Cohort of Monozygotic Twins With Hypertrophic Cardiomyopathy Due to MYBPC3 (Cardiac Myosin-Binding Protein C).

Alfonso Peñarroya, Rebeca Lorca, José Julián Rodríguez Reguero, Juan Gómez, Pablo Avanzas, Juan Ramon Tejedor, Agustín F Fernandez, Mario F Fraga

Abstract readTwin Study
In one paragraph

Article in Journal of the American Heart Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Alfonso PeñarroyaNanomaterials and Nanotechnology Research Center (CINN) Spanish National Research Council (CSIC) El Entrego Asturias Spain.ORCID 0000-0003-4049-6461
Rebeca LorcaHealth Research Institute of the Principality of Asturias (ISPA) Oviedo Asturias Spain.ORCID 0000-0002-7803-4011
José Julián Rodríguez RegueroHealth Research Institute of the Principality of Asturias (ISPA) Oviedo Asturias Spain.
Juan GómezHealth Research Institute of the Principality of Asturias (ISPA) Oviedo Asturias Spain.
Pablo AvanzasHealth Research Institute of the Principality of Asturias (ISPA) Oviedo Asturias Spain.ORCID 0000-0002-4958-6108
Juan Ramon TejedorNanomaterials and Nanotechnology Research Center (CINN) Spanish National Research Council (CSIC) El Entrego Asturias Spain.ORCID 0000-0002-4061-9698
Agustín F FernandezNanomaterials and Nanotechnology Research Center (CINN) Spanish National Research Council (CSIC) El Entrego Asturias Spain.
Mario F FragaNanomaterials and Nanotechnology Research Center (CINN) Spanish National Research Council (CSIC) El Entrego Asturias Spain.ORCID 0000-0001-8450-2603

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHypertrophic cardiomyopathy is an autosomal dominant cardiac disease. The mechanisms that determine its variable expressivity are poorly understood. Epigenetics could play a crucial role in bridging the gap between genotype and phenotype by orchestrating the interplay between the environment and the genome regulation. In this study we aimed to establish a possible correlation between the peripheral blood DNA methylation patterns and left ventricular hypertrophy severity in patients with hypertrophic cardiomyopathy, evaluating the potential impact of lifestyle variables and providing a biological context to the observed changes. METHODS AND

resultsMethylation data were obtained from peripheral blood samples (Infinium MethylationEPIC BeadChip arrays). We employed multiple pair-matched models to extract genomic positions whose methylation correlates with the degree of left ventricular hypertrophy in 3 monozygotic twin pairs carrying the same founder pathogenic variant (

conclusionsWe present a unique pair-matched model, based on 3 monozygotic twin pairs carrying the same founder pathogenic variant and different phenotypes. This study provides further evidence of the pivotal role of epigenetics in hypertrophic cardiomyopathy variable expressivity.

Indexed as

Carrier ProteinsDNA MethylationEpigenesis, GeneticTwins, MonozygoticAdultCardiomyopathy, HypertrophicDiseases in TwinsFemaleGenetic Predisposition to DiseaseHumansHypertrophy, Left VentricularMaleMiddle AgedMyosin Binding Protein CPhenotypeSeverity of Illness IndexCarrier ProteinsMyosin Binding Protein CDNA methylationepigeneticsHCMmonozygotic twinsMYBPC3 pathogenic variantphenotypic expressivity

Identifiers

PMID39470061
PMCPMC11935665

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.